Status:
TERMINATED
Steam Inhalations in COVID-19 Patients
Lead Sponsor:
Meyer Children's Hospital IRCCS
Conditions:
Covid19
Coronavirus Infection
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
The new coronavirus (SARS-CoV-2) causing COVID-19 is an RNA virus coated with a capsid and a peri-capsid crossed by glycoprotein structures. The external proteic structure, which attacks human cells, ...
Eligibility Criteria
Inclusion
- Adults with a SARS-CoV-2 positive molecular swab carried out in the previous 48 hours before the enrollement
- Adults with mild infection
- Adults with symptoms such as fever above 37 ° C, feeling bad, cold symptoms (cough, pharyngodynia, nasal congestion), headache, myalgia, diarrhea, anosmia, dysgeusia
- Adults without the above symptoms
Exclusion
- Adults with dyspnea and/or dehydration and/or alterations in consciousness and/or sepsis.
- Subjects with severe asthma
- Subjects and with contraindications to treatment with steam inhalations
- Multi-allergic subjects
- Subjects unable to complete the protocol
Key Trial Info
Start Date :
January 26 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 6 2021
Estimated Enrollment :
143 Patients enrolled
Trial Details
Trial ID
NCT04743349
Start Date
January 26 2021
End Date
June 6 2021
Last Update
August 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Meyer Children's Hospital
Florence, Italy, 50139